Non-Small Cell Lung Cancer Clinical Trial
Official title:
A Phase 1b Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered With Erlotinib or Alectinib in Patients With Advanced Non-Small Cell Lung Cancer
Verified date | April 2020 |
Source | Hoffmann-La Roche |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This open-label, multicenter study will assess the safety, tolerability, and pharmacokinetics
of intravenous (IV) dosing of atezolizumab in combination with oral erlotinib or alectinib in
participants with NSCLC.
This study has two stages. In the erlotinib group, the combination treatment will be given to
participants with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor
(TKI)-treatment-naive, advanced (nonresectable) NSCLC in a safety-evaluation stage and to
participants with previously untreated EGFR mutation-positive, advanced NSCLC in an expansion
stage (Stage 2). In the alectinib group, for both the safety-evaluation and expansion stages
(Stages 1 and 2), the combination will be given to participants who are treatment-naive with
anaplastic lymphoma kinase (ALK)-positive advanced NSCLC.
In Stage 1, erlotinib will be given at a starting dose of 150 milligrams (mg) by mouth (PO)
once daily (QD) and the starting dose of alectinib will be 600 mg twice daily (BID), for 28
consecutive days during Cycle 1 and on Days 1 through 21 of each cycle thereafter. The
starting dose of atezolizumab will be 1200 mg, administered every 3 weeks (q3W) starting on
Day 8 of Cycle 1. If the starting regimen for a combination treatment is not tolerated,
alternative doses and/or schedules of erlotinib and atezolizumab or alectinib and
atezolizumab may be tested to determine potential recommended Phase 2 dose (RP2D) for that
combination treatment. In Stage 2, a potential RP2D and schedule for each combination
treatment will be investigated in an expansion cohort.
For both stages, continuation of treatment beyond Cycle 1 will be at the discretion of the
treating investigator. Study treatment will be discontinued in participants who experience
disease progression or unacceptable toxicity, are not compliant with the study protocol, or,
in their opinion or in the opinion of the investigator, are not benefiting from study
treatment. However, in the absence of unacceptable toxicity, participants with second-line or
greater NSCLC who are still receiving atezolizumab at the time of radiographic disease
progression may be permitted to continue study treatment.
Status | Completed |
Enrollment | 52 |
Est. completion date | February 5, 2020 |
Est. primary completion date | February 5, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically or cytologically documented, locally advanced or metastatic NSCLC. - Participants in Stage 1 (Safety Evaluation) receiving erlotinib: No limit to the number of prior therapies (except for EGFR TKIs). - Participants in Stage 2 (Expansion) receiving erlotinib: i) sensitizing mutation in the EGFR gene and ii) consent to collection of tumor tissue samples before, during, and after treatment for biopsy and PD biomarker analyses. - Participants receiving alectinib in either Stage 1 or Stage 2: must be ALK positive as assessed by Food and Drug Administration (FDA) approved test and must not have received prior treatment for their advanced NSCLC. - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. - Life expectancy of at least 12 weeks. - Measurable disease, as defined by RECIST Version 1.1 (v1.1). - Adequate hematologic and end-organ function. - Use of highly effective contraception (as defined by protocol) and until 5 months after the last dose of atezolizumab and for 3 months after the last dose of alectinib or for 2 weeks after the last dose of erlotinib, whichever is longer; Males must also refrain from sperm donatation during this same time period. Participants must not be pregnant or breastfeeding. - Archival tumor tissue specimen meeting protocol specifications or the participant will be offered the option of a pre-treatment biopsy to obtain adequate tissue sample. Exclusion Criteria: - For participants receiving erlotinib group: prior treatment with any EGFR mutant-targeting TKI - Any approved anticancer therapy, including chemotherapy, or hormonal therapy (except hormone-replacement therapy or oral contraceptives) within 3 weeks of first dose. - Treatment with any other test drug or participation in another clinical trial within 28 days of enrollment. - Known symptomatic central nervous system (CNS) metastases. Participants with a history of treated or untreated asymptomatic CNS metastases may be eligible. - Leptomeningeal disease. - Uncontrolled tumor-related pain. - Uncontrolled pleural effusion, pericardial effusion, or ascites requiring drainage at least once monthly. - High levels of calcium requiring bisphosphonate therapy or denosumab. - Malignancies other than NSCLC within 5 years prior to enrollment, with the exception of those with a negligible risk of metastasis or death (such as adequately treated carcinoma in-situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer, or ductal carcinoma in situ). - History of severe allergic, anaphylactic, or other reactions to chimeric or humanized antibodies or fusion proteins. - Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation. - History of autoimmune disease. - Participants with prior bone marrow or solid organ transplantation. - History of lung inflammation or disease. - Serum albumin less than (<) 2.5 grams per deciliter (g/dL). - Positive for Human Immunodeficiency Virus (HIV). - Liver disease. - Current or active tuberculosis, hepatitis B, or hepatitis C. - Participants with past or resolved hepatitis B virus (HBV) infection are eligible; participants positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV Riboxy Nucleic Acid (RNA). - Signs or symptoms of infection within 2 weeks prior to first dosing. - Received therapeutic oral or IV antibiotics within 2 weeks prior to first dosing. - Significant cardiovascular disease. - Major surgical procedure other than for diagnosis within 28 days prior to first dosing or during the course of the study. - Administration of a live, attenuated vaccine within 4 weeks before first dosing or during the study. - Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding that may reasonably prevent the participant from participating. - Hypersensitivity to erlotinib or alectinib or to any of the excipients. - Any significant ophthalmologic abnormality. The use of contact lenses is not recommended during the study. - For participants receiving alectinib: baseline Fridericias corrected QT interval (QTcF) greater than (>) 470 milliseconds (ms) or symptomatic bradycardia. - Prior treatment with CD137 agonists or immune checkpoint blockade therapies. - Treatment with systemic immunostimulatory agents within 6 weeks or five half-lives of the drug, whichever is shorter, prior to first dosing. - Treatment with systemic immunosuppressive medications within 2 weeks prior to first dosing (inhaled corticosteroids and mineralocorticoids are allowed). - Participants who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication are elgible for study after discussion and approval by the Medical Monitor. |
Country | Name | City | State |
---|---|---|---|
France | Institut Gustave Roussy | Villejuif | |
Hong Kong | The Chinese University of Hong Kong | Shatin | |
Korea, Republic of | Asan Medical Center | Seoul | |
Korea, Republic of | Seoul National University Hospital | Seoul | |
Spain | START Madrid. Centro Integral Oncologico Clara Campal; CIOCC | Madrid | |
Spain | Hospital Clinico Universitario de Valencia | Valencia | |
United Kingdom | Queen Mary University of London | London | |
United States | Beth Israel Deaconess Med Ctr; Neurology/MS Center | Boston | Massachusetts |
United States | Dana Farber Cancer Institute | Boston | Massachusetts |
United States | Massachusetts General Hospital;Hematology/ Oncology | Boston | Massachusetts |
United States | University of Chicago | Chicago | Illinois |
United States | Case Western Reserve University; Medicine-Hematology and Oncology | Cleveland | Ohio |
United States | Karmanos Cancer Center; Department of Oncology | Detroit | Michigan |
United States | Yale University School Of Medicine | New Haven | Connecticut |
United States | Memorial Sloan Kettering - Basking Ridge | New York | New York |
United States | UC Irvine Medical Center | Orange | California |
United States | Florida Hospital Cancer Inst | Orlando | Florida |
Lead Sponsor | Collaborator |
---|---|
Hoffmann-La Roche |
United States, France, Hong Kong, Korea, Republic of, Spain, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants with Dose-Limiting Toxicities (DLTs) | 28 days | ||
Primary | Recommended Phase II Dose (RP2D) of Atezolizumab and Erlotinib | 28 days | ||
Primary | Recommended RP2D of Atezolizumab and Alectinib | 28 days | ||
Secondary | Minimum Plasma Concentration (Cmin) of Alectinib and Major Metabolites, as Appropriate | Pre-dose (0 hour) on Day 1 of Cycles 1-4, Day 8 of Cycle 1 (Cycle 1 =28 days; Cycle 2 onwards=21 days) | ||
Secondary | Progression-Free Survival (PFS) as Assessed Using the Response Evaluation Criteria in Solid Tumors (RECIST) | First dose of study treatment up to disease progression or death from any cause (up to approximately 6 years) | ||
Secondary | Overall Survival | First dose of study treatment up to death from any cause during the study (up to approximately 6 years) | ||
Secondary | Percentage of Participants with Objective Response (Complete Response [CR] or Partial Response [PR]) Using RECIST | Baseline up to disease progression or death from any cause (up to approximately 6 years) | ||
Secondary | Percentage of Participants with Adverse Events | Baseline up to approximately 6 years | ||
Secondary | Percentage of Participants with Anti-Drug Antibodies (ADAs) Against Atezolizumab | Baseline up to approximately 6 years | ||
Secondary | Maximum Serum Concentration (Cmax) of Atezolizumab | Day 1 of Cycles 1-4, Day 8 of Cycle 1 (Cycle 1 =21 days; Cycle 2 onwards=28 days) | ||
Secondary | Minimum Serum Concentration (Cmin) of Atezolizumab | Pre-dose (0 hour) on Day 1 of Cycles 1, 2, 3, 4, 6, and 8 and at study termination (up to approximately 5 years; Cycle 1=21 days; Cycle 2 onwards=28 days) | ||
Secondary | Maximum Plasma Concentration (Cmax) of Erlotinib | Day 1 of Cycles 1-4, Day 8 of Cycle 1 (Cycle 1 =21 days; Cycle 2 onwards=28 days) | ||
Secondary | Minimum Plasma Concentration (Cmin) of Erlotinib | Pre-dose (0 hour) on Day 1 of Cycles 1-4, Day 8 of Cycle 1 (Cycle 1 =21 days; Cycle 2 onwards=28 days) | ||
Secondary | Maximum Plasma Concentration (Cmax) of Alectinib and Major Metabolites, as Appropriate | Day 1 of Cycles 1-4, Day 8 of Cycle 1 (Cycle 1 =21 days; Cycle 2 onwards=28 days) | ||
Secondary | Duration of Objective Response as Assessed Using RECIST | First occurrence of a documented objective response up to disease progression or death from any cause (up to approximately 6 years) | ||
Secondary | Percentage of Participants with Best Overall Response | Baseline up to disease progression or death from any cause (up to approximately 6 years) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03087448 -
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
Recruiting |
NCT05042375 -
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Terminated |
NCT05414123 -
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
|
||
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Recruiting |
NCT05009836 -
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03219970 -
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
|
||
Recruiting |
NCT05949619 -
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04054531 -
Study of KN046 With Chemotherapy in First Line Advanced NSCLC
|
Phase 2 | |
Withdrawn |
NCT03519958 -
Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
|
||
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Terminated |
NCT02580708 -
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01871805 -
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05919641 -
LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
|
||
Completed |
NCT03656705 -
CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma
|
Phase 1 |